Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S2215-0366(19)30392-X | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms.
BMC Med
January 2025
Lurie Center for Autism, Massachusetts General Hospital, Lexington, MA, 02421, USA.
Background: The prevalence of autism spectrum disorder (ASD) has surged, with an estimated 1 in 36 eight-year-olds in the United States meeting criteria for ASD in 2020. Autistic individuals face elevated rates of co-occurring medical, psychiatric, and behavioral conditions compared to non-autistic individuals. The rising ASD-patient demand is increasingly outpacing the capacity of ASD-specialty clinics, resulting in urgent need for autism-competent providers in general practice settings.
View Article and Find Full Text PDFTransitioning From Pediatric to Adult Psychiatric Care for ADHD in Sweden: A Nationwide Study.
J Atten Disord
February 2025
Northern Stockholm Psychiatry, Sweden.
Objective: To evaluate care transition and medication use in young adults with ADHD in Sweden.
Method: Observational retrospective study of patients with ADHD from the Swedish National Patient Register, Prescribed Drug Register, and Cause of Death Register (2018-2020). Last contact with pediatric psychiatric care, first contact with adult psychiatric care, and medication use were described for ages 18 to 21 years, inclusive.
Therapeutic drug monitoring vs. pharmacogenetic testing in the context of elevated olanzapine concentrations and prior clozapine intolerability: a case study.
BMC Psychiatry
December 2024
University of California, Irvine, School of Medicine, 1001 Health Sciences Road, Irvine, CA, 92697, USA.
Article Synopsis
- Strong evidence supports therapeutic drug monitoring (TDM) for olanzapine and clozapine, but TDM for olanzapine is often underused despite its effectiveness.
- A case study of a 32-year-old male with schizoaffective disorder demonstrated that while olanzapine dosing revealed high levels indicating poor metabolism, pharmacogenetic tests did not provide useful information about his drug metabolism.
- The conclusion emphasizes the importance of TDM over pharmacogenomic testing for managing medications like olanzapine and clozapine, especially in patients suspected of having altered CYP1A2 metabolism.
Prenatal environmental risk factors for autism spectrum disorder and their potential mechanisms.
BMC Med
September 2024
The Institute for Mental and Physical Health and Clinical Translation (IMPACT), Deakin University, Geelong, Australia.
Article Synopsis
- * Key prenatal risk factors have been identified, such as maternal infections, gestational diabetes, and obesity, which are linked to the development of ASD.
- * Current research is exploring additional prenatal exposures, like medication use and pollutants, and the mechanisms behind these factors, to find new ways to prevent ASD.
Trends and Prevalence of Psychotropic Medication Use in Children and Adolescents in the Period Between 2013 and 2023: A Systematic Review.
Cureus
March 2024
Psychiatry, College of Medicine, Taif University, Taif, SAU.
Mental health problems among children and adolescents are a significant global public health concern, with a prevalence of approximately 10-20%. Psychotropic medications, including stimulants, antipsychotics, antidepressants, and mood stabilizers, have been proven effective in treating various psychiatric disorders among children and adolescents. Despite the common use of these medications, they have various side effects and complications.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!